Impartial, objective gap analysis is a critical component of your NDA/BLA/PMA. PharmaNet Consulting professionals can review your product development plan, evaluate whether your study design is sufficiently thorough and robust, identify potential regulatory risks, suggest corrective measures, and assess your chances for first-pass approval.
PharmaNet professionals available for consultation on this topic include:
Vice President, PharmaNet Consulting
Senior Vice President, PharmaNet Consulting
Joyce Lea Frey-Vasconcells, PhD
Executive Director, PharmaNet Consulting
Senior Vice President, Regulatory Affairs Worldwide
504 Carnegie Center, Princeton, NJ 08540